New approaches to psoriasis treatment. A review

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 13, Issue 2, 2004, Pages 50-57

  Godić, Aleksandar ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Alefacept; Aspects; Efalizumab; Etanercept; Genetics; Immunologic; Infliximab; Oprelevkin; Psoriasis; Treatment

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; BITUMINOSULFONIC ACID SALT; CALCITRIOL; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; FUMARIC ACID DERIVATIVE; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PYRITHIONE ZINC; RECOMBINANT INTERLEUKIN 11; RETINOID; SELENIUM SULFIDE; SULFONIC ACID DERIVATIVE; TACROLIMUS; TAR; TIOGUANINE; TIOXOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VITAMIN D DERIVATIVE;

AUTOIMMUNITY; AUTOSOMAL DOMINANT INHERITANCE; BALNEOTHERAPY; CHILL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DERMIS; EXCIMER LASER; FEVER; GENE EXPRESSION; GENE LOCUS; GENETICS; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; MULTIFACTORIAL INHERITANCE; MYALGIA; NAUSEA; PROTEIN EXPRESSION; PSORIASIS; PSORS1 GENE; PSORS8 GENE; PUVA; REVIEW; SIDE EFFECT; SYNDROME; T LYMPHOCYTE ACTIVATION;

EID: 3142746641     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
2. Espinoza LR, Cuellor ML, Silveira LH. Psoriatic arthritis. Curr Opin Rheumatol 1992; 4: 470-8.
3. Barker JNWN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26: 321-5.
4. Nair RP, Hensler T, Jenisch S et al.vidence for two psoriasis susceptibility loci (HLA and 17q) and two no el candidate regions (16q and 20p) by genome wide scan. Hum Mol Genet 1997; 6: 1349-56.
5. Krueger JG. The immunologic basis for treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46(1): 1-23.
6. Beutner EH, Jablonska S, Jarzabek CM, et al. Studies in immunodermatology. VI IF studies of autoantibodies to the stratum corneum and of in vivo fixed IgG in stratum corneum of psoriatic lesions. Int Arch Allergy Appl Immunol 1975; 48: 301-23.
7. Kang S, Voorhees JJ. Immunopathogenesis. In: Van de Kerkhof PCM, ed. Textbook of psoriasis. Oxford, Blackwell Science, 1999: 106-18.
8. Baadsgaard O, Gupta AK, Taylor RS, et al. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen presenting cells. J Invest Dermatol 1989; 92: 190-5.
9. Prinz JC. Psoriasis vulgaris, a sterile antibacterial skin reaction, mediated by cross-reactive T-cells? An immunological view on the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-32.
10. Smith CH, Barker JNWN. Cell trafficking and role of adhesion molecules in psoriasis. In: van de Kerkhof, Bos JD, eds. Pathogenic aspects of psoriasis. New York, Elsevier 1995; 13: 151-60.
11. Leung DYM, Gately M, Trumble A, et al. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen (CIA). J Exp Med 1995; 191: 747.
12. Baker CG. Moisturization: new methods to support time proven ingredients. Cosmet Toilet 1987; 102: 99-102.
13. Huber C, Christopher E. Keratolytic effect of salicylic acid. Arch Dermatol Res 1977; 257: 293-7.
14. Lewkaya DA, Sefton J, Krueger FF, et al. Safety and efficacy of a new retinoid gel in the treatment of psoriasis. J Invest Dermatol 1992; 98: 600.
15. Van de Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995; 132: 675-82.
16. Hradil E, Lindström C, Müller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol 1978; 58: 373-3.
17. Katz HI, Hien NT, Prower SE, et al. Betamethasone in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123: 1308-11.
18. Timonen P, Friend O, Abeywickrama K, et al. Efficacy of low dose cyclosporin A in psoriasis: results of dose finding studies. Br J Dermatol 1990; 122: 33-40.
19. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol 1988; 19: 458-69.
20. Gollnick H, Zuan H, Ruzicka T, et al. Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double blind multicenter half-year follow-up study. Eur J Dermatol 1993; 3: 442-6.
21. Van de Kerkhof PCM, Mali JWH. Methotrexate maintenance following ingram therapy in difficult psoriasis. Br J Dermatol 1982; 106: 623-7.
22. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 patients. Danish Med Bull 1978; 25: 208-11.
23. Zachariae E, Zachariae H. Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol 1987; 67: 270-3.
24. Grundmann-Kollman M, Korting HC, Behrens S, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-7.
25. Altmeyer PY, Mattheus U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
26. Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamni D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070-8.
27. Layton AM, Sheehan-Dove RA, Goodfild MJD, et al. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121: 647-53.
28. Zackheim HS, Glogau RG, Fisher DA, et al. 6-thioguanine treatment of psoriasis. J Am Acad Dermatol 1994; 30: 452-8.
29. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 6: 343-50.
30. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981; 76: 359-62.
31. Tanew A, Radakovic-Fijan S, Schemper M, et al. Narrow band UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999; 135: 519-24.
32. Boehncke WH, Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 2000; 136: 271-2.
33. Bonis B, Kememy L, Dobozy A, et al. 308-nm UVB excimer lasers for psoriasis. Lancet 1997; 350: 1522.
34. Smit J, de Jong E, van Hooijdonk C, et al. A multicenter phase II clinical and immunohistochemical trial of systemic bexarotene (Targetin) in psoriasis. J Invest Dermatol 2000; 114: 776.
35. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995; 133: 426-32.
36. Ryffel B. Safety of human recombinant proteins. Biomed Environ Sci 1997; 10: 65-72.
37. Choy EH. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 1998; 12: 139-48.
38. Parren PW. Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum Antibodies Hybridomas 1992; 3: 137-45.
39. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of a psoriasis to a lymphocyte-selective toxin (DAB389-IL2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-7.
40. +) is linked to serum levels of LFA3TIP. J Invest Dermatol 2000; 114: 776.
41. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Eng J Med 2001; 345: 248-55.
42. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol 2002; 138: 657-63.
43. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-10.
44. Damle NK, Klussman K, Linsley PS, et al. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992; 148: 1985-92.
45. Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235-53.
46. Gottlieb A, Miller B, Chaundhari U, et al. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis. J Invest Dermatol 2000; 114: 840.
47. Finkelman FD. Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 1995; 182: 279-82.
48. Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatmenet of psoriasis: clinical results of a phase II trial. Arch Dermatol 1999; 135: 187-92.
49. Asadullah K, Sterry W, Ebeling M, et al. Clinical and immunological effects of IL-10 therapy in psoriasis. Br J Dermatol 1999; 141: 989.
50. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
51. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
52. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
53. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697-702.
54. Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39: 141-8.
55. Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT-3 induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993; 25: 89-92.
56. Abramovits W. Raptiva (efalizumab). Skin Med 2004; 3: 37-8.